InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Update on Revenue Recognition Review
November 22, 2022
Vivos Therapeutics (NASDAQ: VVOS) is a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults. The company today provided an update on its review of its revenue recognition policies and the expected timing for the release of its second and […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Q2 Earnings Delay
August 23, 2022
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, has reported a delay in releasing its Q2 2022 financial earnings. The company reported that its independent registered public accountants noted a possible need […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Reschedule Release of Q2 2022 Financial Results
August 15, 2022
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, has announced that it will be rescheduling the release of its Q2 2022 financial results, which is for the period ended June 30, 2022; […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Q2 2022 Call to Discuss Financial Results
August 9, 2022
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, will release its second quarter 2022 financial results on Aug. 15, 2022, after market close. In conjunction with that, the company has also scheduled […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Receives Regulatory Clearances in Australia for Line of Oral Appliances
July 14, 2022
Vivos Therapeutics (NASDAQ: VVOS), a revenue-generating medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, has been cleared to treat obstructive sleep apnea in Australia; the clearance allows the company to treat all ages, regarding of severity. The […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Enters Strategic Distribution Agreement with GM Instruments
June 29, 2022
Vivos Therapeutics (NASDAQ: VVOS) is a revenue-stage medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults. The company today announced its entry into an exclusive agreement with GM Instruments Ltd. for the distribution of GM Instruments’ NR6 Rhinomanometer, […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Presents Sleep Apnea Study Results at Annual SLEEP 2022 Event
June 14, 2022
Vivos Therapeutics (NASDAQ: VVOS), a revenue-generating medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults, shared results from its retrospective study during SLEEP 2022, the annual meeting of the Associated Professional Sleep Societies. Vivos Medical Advisory Board member […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Participation in Annual SLEEP 2022 Event
May 26, 2022
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, will be attending and presenting at SLEEP 2022. The event is the annual meeting of the Associated […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q1 2021 Financial, Operational Report
May 17, 2022
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults, is reporting its financial results and operating highlights for the first quarter ended March 31, 2022. Highlights […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Schedules Release of Q1 2022 Results, Conference Call
April 28, 2022
Vivos Therapeutics (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults. The company today announced plans to release its financial results for the first quarter ended March […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Opens Third US Multidisciplinary Sleep Apnea Clinic
April 26, 2022
Vivos Therapeutics (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snoring. The company today announced that Vivos’ medical integration division will open its third U.S. multidisciplinary sleep apnea clinic […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q4, Full-Year 2021 Financial, Operational Report
April 1, 2022
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults, is reporting its financial results and operating highlights for the fourth quarter and full year ended Dec. […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Call to Review Q4, FY 2021 Financial Results
March 31, 2022
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (“OSA”) and snoring, has scheduled a conference call to discuss financial results that will be reported today after market close. The financial results will […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Selected Among ‘World’s Most Innovative Companies’ by Fast Company Magazine
March 8, 2022
Vivos Therapeutics (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snoring. Vivos Therapeutics today announced that Fast Company magazine has selected Vivos and its novel and proprietary technology for […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Rebrands Proprietary Offering of Clinical Treatment Devices, Modalities and Protocols
March 3, 2022
Vivos Therapeutics (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snoring. The company today announced a rebranding of its proprietary offering of clinical treatment devices, modalities and protocols, now […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Plans to Participate in Investor Conferences
March 2, 2022
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (“OSA”) and snoring, will be presenting at two upcoming investor conferences. According to the company, VVOS CEO Kirk Huntsman will participate in the Q1 […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Participate in 2022 World Sleep Congress
February 24, 2022
Vivos Therapeutics (NASDAQ: VVOS) Medical Advisor Board has been invited to present at the upcoming World Sleep Congress. The event, slated for March 11–16, 2022, will be held in Rome. Members of the board will be presenting a summary review of sleep-therapy data from patients treated with the Vivos Method. Vivos is a medical technology […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Files for US Patent on Proprietary New and Enhanced Clinical Protocols
January 27, 2022
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”) and snoring, today announced the filing of a U.S. patent application related to certain new and enhanced clinical methods and protocols developed within its proprietary Vivos Method treatment […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Info Gathered during Sleep Apnea Diagnostic Testing
January 19, 2022
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, is reporting significant increases across several key metrics for its SleepImage Home Sleep Apnea Tests (“HST”) during the three-month period that ended Dec. 31, […]
InvestorNewsBreaks – Vivos Therapeutics Inc.’s (NASDAQ: VVOS) mmRNA Device Now Covered by, Billable to Medicare
December 14, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”) and snoring, today announced that it has received acceptance from a Centers for Medicare & Medicaid Services Pricing, Data Analysis and Coding (“PDAC”) contractor for its mmRNA (modified […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Officially Registers with Health Canada
December 9, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, has registered with Health Canada, a key step in being able to manufacture and sell its proprietary sleep disorder, snoring and sleep apnea appliances […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Present at Benzinga Global Small Cap Conference
December 3, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”) and snoring, today announced that its chairman and CEO Kirk Huntsman and CFO Brad Amman will be presenting at the online Benzinga Global Small Cap Conference. The event […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q3 2021 Financial, Operational Report
November 16, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults, has released is third-quarter 2021 financial report; the company also reported on operational highlights. The report noted that VVOS Q3 revenue increase […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Participation at Q4 Virtual Investor Summit
November 15, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”), will be presenting at the upcoming Q4 Virtual Investor Summit. The summit is scheduled for Nov. 17, 2021. Vivos CEO Kirk Huntsman, chief financial officer Brad Amman, and investor relations officer […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Scheduled Release of Q3 2021 Financial Results, Conference Call
November 9, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults, today announced that it plans to release financial results for the third quarter ended Sept. 30, 2021, after market close on Monday, […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Present at Benzinga Global Small Cap Conference
October 22, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, today announced that its chairman and CEO Kirk Huntsman and CFO Brad Amman will be presenting at the online Benzinga Global Small Cap Conference. […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Showcasing Innovations in OSA Treatment at 2021 Annual Breathing Wellness Conference
October 20, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, has announced the commencement of the 3rd-annual Breathing Wellness Conference presented by The Vivos Institute. The event is taking place at Caesars Palace in Las Vegas, Nevada, […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS), Candid to Bring Airway and Sleep, Oral Health, Orthodontic Therapy Together in Comprehensive Solution
October 19, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, and Candid Care Co., a digital platform for oral healthcare, have announced a new collaboration. Under the partnership, the companies will seek to provide patients with a […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS), Candid Collaborate to Deliver Comprehensive Treatment Solution
October 18, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, and Candid Care Co., a digital platform for oral healthcare, today announced a new collaboration. The partnership will seek to provide patients with a comprehensive, whole-mouth solution […]
InvestorNewsBreaks – Vivos Therapeutics Inc.’s (NASDAQ: VVOS) Guides Demonstrate Significant Reduction of Pediatric Tooth Decay in Peer-Reviewed Study
October 13, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (“OSA”), today announced results from a peer-reviewed, published study by an independent dentist. The findings demonstrate a significant reduction of tooth decay in pediatric patients after undergoing […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Forms Medical Consortium to Advance OSA Technology
September 23, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (“OSA”), today announced the official formation of the Vivos Medical Consortium. According to the update, this physician working group, led by Drs. Clete Kushida of Stanford University […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Present at Benzinga Healthcare Small Cap Conference
September 22, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (“OSA”), today announced that its chairman and CEO Kirk Huntsman and CFO Brad Amman will be presenting at the online Benzinga Healthcare Small Cap Conference at 2:20 […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Participate at H.C. Wainwright 23rd Annual Global Investment Conference
September 8, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”) and snoring, today announced its participation at the H.C. Wainwright 23rd Annual Global Investment Conference. Vivos CEO Kirk Huntsman will be presenting at the event beginning at 7:00 a.m. EDT on […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Partners with Empower Sleep in Effort to Improve OSA Diagnosis, Treatment
August 26, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), is teaming up with Empower Sleep. Vivos and the California-based company, which works to empowering patients with affordable, accessible and personalized telemedicine sleep care, are […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Receives FDA Clearance for mmRNA Oral Appliance
August 23, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has received 510(k) market clearance from the FDA for its modified mandibular repositioning nighttime appliance (“mmRNA”). The device is designed to treat mild-to-moderate OSA in […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Detailed Summary of National Study
August 18, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has released a detailed summary of the results from its most recent national study. Those results include the fact that one in four patients in […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q2 2021 Financial, Operational Report
August 13, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has announced its most recent financial report, along with operational highlights for the second quarter, the period ended June 20, 2021. In part, the report […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Participation in Q3 Virtual Investor Summit
August 10, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), will participate in the upcoming two-day Q3 Virtual Investor Summit. Vivos CEO Kirk Huntsman along with CFO Brad Amman and Ed Loew, Vivos investor relations […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Conference Call to Discuss Q2 2021 Financial Results
August 9, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has scheduled a conference call and live webcast for Aug. 12, 2021, to begin at 5 p.m. ET. The purpose of the call is to […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Opening of Denver-Based State-of-the-Art International Training Center
July 29, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), today announced that it has opened the Vivos Institute training center in Denver, Colorado. The 15,000-square-foot facility was established to provide advanced post-graduate education and […]